Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics 已爲其 1/2 期研究中的第一位患者施用藥物，以評估 Bria-OTS 的安全性和有效性，Bria-OTS 是 Briacell 的個性化下一代免疫療法。
The study will investigate Bria-OTS alone and in combination with immune check point inhibitor tislelizumab (manufactured and supplied by BeiGene) for the treatment of metastatic breast cancer.
該研究將研究Bria-OTS單獨使用及與免疫檢查點抑制劑tislelizumab（由百濟神州製造和供應）聯用治療轉移性乳腺癌。
Bria-OTS is an enhanced form of Bria-IMT, currently in pivotal Phase 3 study for metastatic breast cancer.
Bria-OTS是Bria-IMt的增強形式，目前正處於轉移性乳腺癌的關鍵第三階段研究中。
資訊熱榜
更新時間